tbuckley/cabot-search huggingface dataset:
FRI0055 The influence of cigarette smoking on disease activity and joint erosions in rheumatoid arthritis: a systematic review and meta-analysis.
Authors: J. Castellanos-De La Hoz, J. Amaya-Amaya, N. Molano-González, F. Gutiérrez-Infante, J. M. Anaya, A. Rojas-Villarraga
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> There is a clear causal relationship between tobacco smoking and rheumatoid arthritis (RA), supported by observational studies and systematic reviews (1); however, the effect of smoking on disease activity and the development of joint surface erosions has not been clearly established. Current data are conflicting, with some studies reporting an increased activity and progression (2,3) of erosions and others showing an opposite relationship (4). <h3>Objectives</h3> To summarize through a systematic review and meta-analysis of available data in the literature about cigarette smoking and RA, regarding its effect on disease activity and radiographic progression. <h3>Methods</h3> The systematic search was done following PRISMA guidelines in the Medline, EMBASE databases up to August 2012 and databases alerts until November 2012. Additional studies were identified from the EULAR and ACR congresses from 2000 to 2012 and article references. Search terms included "smoking", "tobacco", "smoke", "cigarette" and "rheumatoid arthritis". Any type of study done with RA cases, defined by accepted classification criteria and having information about the relationship between cigarette smoking and DAS28 or erosion score was considered for inclusion. A common effect size was calculated based on a random effects model. <h3>Results</h3> Out of a total of 2215 articles retrieved, 43 articles met inclusion. Of these, 27 were included in the meta-analysis. Twelve contained information about DAS28 and 17 about radiographic progression. There was a negative association between smoking and EULAR response (OR: 0.72; 95% CI:0.57-0.91; p-value:0.005) and DAS28 remission (OR:0.78; 95%CI:0.63-0.96; p-value:0.023). DAS28 was significantly higher in current smokers (MD:0.29; 95% CI:0.12-0.44;p-value:&lt;0.001) as well as erosive score (SMD:0.38;95% CI:0.04-0.72; p-value:0.028). Data was ambiguous for erosion progression during follow-up (OR: 0.93; 95% CI: 0.72-1,2; p-value:0.59). A sensitivity analysis confirmed that the results were not sensitive to restrictions on the data included. Publication bias was trivial. <h3>Conclusions</h3> Cigarette smoking is associated with a diminished response to treatment (by the EULAR criteria) and an increased erosion score. However, an increased rate of radiographic progression was not demonstrated in smokers. Prospective studies are warranted for this topic. <h3>References</h3> Sugiyama D, et al. Ann Rheum Dis 2010;69:70-81. Saag KG, et al. Ann Rheum Dis 1997;56:463-9. Papadopoulos NG, et al. Clin Exp Rheumatol 2005;23:861-6. Salliot C, et al. Arthritis Rheumatism 2009;60:364. <h3>Disclosure of Interest</h3> None Declared
P12.11 * IS INTRAOPERATIVE LANGUAGE MAPPING USEFUL FOR SURGICAL RESECTION OF HIGH GRADE GLIOMAS INVOLVING LANGUAGE AREAS?
Authors: M. Riva, A. Comi, A. Casarotti, E. Fava, T. Alfiero, F. Pessina, L. Bello
Journal: Neuro-Oncology (2014)

Intraoperative language mapping is standard for resection of gliomas involving language pathways, because it enables a maximal safe tumor removal. Intraoperative language mapping is a demanding procedure requiring a good level of patient collaboration, a complex peri-operative organization, and may cause patient fatigue. The selection of patients to submit to such a procedure is critical. The efficacy of intraoperative mapping is widely recognized for Low Grade Gliomas, the use for surgical removal of high grade gliomas (HGGs) is still under debate. We evaluated the efficacy of the use of intraoperative language mapping for resection of HGGs involving language pathways, to identify for which subtype of patients is highly recommended, and for which can be optional. 2 groups were included. In the first group (126 patients) removal was performed asleep, with the aid of neurophysiological monitoring. In the second group (157 patients) resection was performed awake with the aid of cortical and subcortical language mapping and neurophysiological monitoring. Patients and tumor characteristics (location, radiological appearance on conventional MR, pattern of tract dislocation/infiltration in DTI FT images) were considered. Results were evaluated as immediate/permanent deficits (by neuropsychological evaluation) and extent of resection (on volumetric gadolinium enhanced T1 weighted MR images). In the first group, 65 tumors were frontal, 61 temporal. 108 were involving the cortex, 18 were deep seated. DTI depicted the Tract located at the tumor periphery in 111 patients, inside the tumor in the remaining. 32 patients had pre-operative mild or moderate language deficits. Resection was continued till microscopically normal parenchyma was encountered. Total resection was achieved in 97.6% of cases. In 35 (27.8%) of patients, immediate post-operative deficits were observed, which remained as permanent in 16 patients. 87.5% of patients with pre-operative language deficits recovered in the post operative period. Patients who developed permanent deficits were those with deep seated tumors. In the second group of tumors, 72 were frontal, and 85 temporal, 112 superficial, 45 were not reaching the cortex. DTI depicted the tract located in the tumor periphery in 128 patients, inside the tumor in the remaining. 25 patients had pre operative mild language deficits. Resection was continued till functional boundaries were reached. Immediate post operative language deficits were shown in 41 (26.1%) patients, with complete recovery within a month in all patients. Total resection was reached in 96.1% of cases. Removal of language pathways tumors does not strictly requires the use of subcortical language mapping when the tumor reach the surface. Resection of deep seated tumors or of tumors with infiltrated tracts (as depicted by DTI) requires the use of subcortical mapping to achieve a safe tumor removal.
A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation
Authors: Thomas C. Merigan, Dale G. Renlund, Susan Keay, Michael R. Bristow, Vaughn Starnes, John B. O'Connell, Silvia Resta, Diane Dunn, Patricia Gamberg, Ranae M. Ratkovec, Wayne E. Richenbacher, Roger C. Millar, Charles DuMond, Bernadette DeAmond, Veronica Sullivan, Tricia Cheney, William Buhles, Edward B. Stinson
Journal: New England Journal of Medicine (1992)

Because of the immunosuppression required, heart-transplant recipients frequently have complications caused by cytomegalovirus (CMV), including pneumonia, esophagitis, gastritis, and a syndrome of fever, hepatitis, and leukopenia. We undertook a controlled trial to evaluate the prophylactic administration of ganciclovir to prevent CMV-induced disease after heart transplantation.
FDG PET/CT in Evaluation of Unusual Cutaneous Manifestations of Breast Cancer
Authors: Shaylee R. Dave, Thomas A. Samuel, Darko Pucar, Natasha Savage, Hadyn T. Williams
Journal: Clinical Nuclear Medicine (2014)

Cutaneous metastases of primary internal malignancies are rare, with an incidence of 0.7% to 10.4%. Cutaneous manifestations due to breast cancer are the most common metastases dermatologists observe, with a prevalence of 2.4% and an incidence of 23.9%. Presence of cutaneous metastases is usually a late event in disease progression, indicating grave prognosis. Recognition of cutaneous breast cancer metastases significantly alters therapeutic plans, especially when the disease was thought to be successfully cured. F-FDG PET CT imaging can detect cutaneous metastasis and sites of distant metastases and monitor response to therapy. We report 3 patients with cutaneous-predominant breast carcinoma seen by FDG PET/CT.
Abstract 2123: Tetrandrine impairs prostate cancer cell survival in part by inhibiting AR signaling pathway.
Authors: Sweaty Koul, Hari K. Koul
Journal: Cancer Research (2013)

Abstract Prostate cancer (PCa) is the second leading cause of cancer deaths in men, and the majority of prostate cancer deaths are a result of emergence of castrate resistant phenotype. Our previous studies indicated that Tetrandrine (TET), a bis-benzylisoquinoline alkaloid isolated from the root of Stephania tetrandra inhibited cell cycle progression and promoted growth arrest at lower concentrations and promoted apoptosis at higher concentrations and at longer time points. AR signaling is known to play a critical role in androgen responsive prostate cancer cells. In the present studies we evaluated the effects of TET on AR signaling in androgen dependent (LNCaP cells) as well as castrate resistant (C4 and C42B cells, castrate resistant lineages of LNCaP cells) prostate cancer cells. Exposure of LNCaP cells to Tet resulted in a dose and time dependent decrease in PSA protein (cell associated as well as secreted PSA). Further analysis revealed that Tet also decreased PSA mRNA as well as PSA promoter activity, suggesting that Tet induced decrease in PSA was a result of inhibition of PSA transcription. Since PSA is known to be an AR responsive gene, these results led us to investigate the effects of Tet on AR signaling. Results from these studies revealed that Tet inhibited AR activity as measured by TARP promoter assay. Taken together these studies suggest that Tet targets AR signaling pathway effectively blocking AR target genes. In summary our results suggest that Tet by inhibiting AR signaling pathway may work as an effective therapeutic agent in prostate cancer, for which there is no cure to date. Grant Support: Studies supported in part by VA Merit Award-01BX001258 (HK), NIH/NCI R01CA161880 (HK) and Department of Surgery, School of Medicine chair commitment (HK). Citation Format: Sweaty Koul, Hari K. Koul. Tetrandrine impairs prostate cancer cell survival in part by inhibiting AR signaling pathway. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2123. doi:10.1158/1538-7445.AM2013-2123
APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl
Authors: T Wakioka, A Sasaki, K Mitsui, M Yokouchi, A Inoue, S Komiya, A Yoshimura
Journal: Leukemia (1999)
AB0691 Association between MRI Inflammation and Disease Activity in Early Axial Spondyloarthritis
Authors: E. Gubar, A. Smirnov, E. Tukhova, T. Dubinina, A. Demina, A. Godzenko, O. Rumyantseva, S. Shubin, S. Gluhova, S. Erdes
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The relationship between MRI inflammation and disease activity in early axial spondyloarthritis has not been proved sufficiently. <h3>Objectives</h3> Establishing the association between clinical activity and MRI inflammation of sacroiliac joints (SIJs), lumbar spine (LS) and hip joints (HJs) in early axial spondyloarthritis (axSpA) patients (pts). <h3>Methods</h3> 73 pts (33 men and 40 women) with early axSpa were examined: disease duration – 19.9±14.4 months. Pts fulfilled ASAS criteria. Age – 28.3±6.4 years, BASDAI – 4.1±1.9; ASDAS-CRP – 2.7±1.3; ESR – 21.9±17.6; CRP – 29.0±38.5; 66 (90.4%) pts were HLA-B27 positive. High disease activity was assumed in cases where BASDAI ≥4, ASDAS-CRP ≥2.1. MRI of SIJs, LS and hip joints (in case of hip joint involvement) was performed on Signa Ovation 0,35 T scanner (matrix 288x192). <h3>Results</h3> MRI inflammation of SIJs and/or LS and/or HJs has been found in 62 (84.9%) pts: SIJs – in 53 (72.6%) pts, HJs – in 21 (28.7%) pts and LS, – in 8 (11.0%) pts. 42 out of 62 (67.7%) pts that had MRI inflammation in at least one of the three studied sections, had high ASDAS-CRP activity; and out of the group of patients without MRI inflammation (n=11) high ASDAS-CRP has been detected in 4 (36.4%) pts (p=0.047). High ASDAS-CRP activity was observed in 38 out of 53 (71.7%) pts that had active sacroiliitis (SI); out of the group of pts without MRI SI (n=20), high ASDAS-CRP was observed in 8 (40.0%) pts (p=0.012). No association has been found between MRI data and disease activity according to BASDAI. <h3>Conclusions</h3> Correlation has been detected between inflammatory lesion in SIJs and/or LS and/or HJs and high disease activity according to ASDAS-CRP. There is an association between existence of active MRI SI and high ASDAS-CRP activity. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4134
Abstract 3068: MicroRNA 4723-5p is novel tumor suppressor microRNA in prostate cancer that directly regulates Abelson family of nonreceptor protein tyrosine kinases.
Authors: Sumit Arora, Sharanjot Saini, Shahana Majid, Varahram Shahryari, Soichiro Yamamura, Takeshi Chiyomaru, Shinichiro Fukuhara, Inik Chang, Guoren Deng, Yuichiro Tanaka, Rajvir Dahiya
Journal: Cancer Research (2013)

Abstract The Abelson (c-Abl) proto-oncogene encodes a highly conserved nonreceptor protein tyrosine kinase that has been implicated in many cellular processes including regulation of cell growth and survival, oxidative stress and DNA-damage responses, actin dynamics and cell migration. Aberrant activity of this tyrosine kinase has been implicated in the stimulation of cancer growth and progression. Abl tyrosine kinase represents a target for specific anti-cancer therapy in prostate cancer and Abl inhibitors are being tested clinically for the treatment of prostate cancer bone metastasis. Here we report that Abl kinases are regulated by a novel microRNA- miR-4723-5p in prostate cancer. Expression profiling of miR-4723-5p expression in a cohort of prostate cancer clinical specimens showed that miR-4723-5p expression is widely attenuated in prostate cancer. Low miR-4723-5p expression was significantly correlated with poor survival outcome and tumor progression and recurrence in prostate cancer. Further, our analyses suggest that miR-4723-5p has significant potential as a disease biomarker for diagnosis and prognosis in prostate cancer. To evaluate the functional significance of decreased miR-4723-5p expression in prostate cancer, miR-4723-5p was reintroduced in prostate cancer cell lines followed by functional assays. The over expression of miR-4723-5p led to significant decreases in cell growth, clonability, invasion and migration. Importantly, miR-4723-5p reexpression led to dramatic induction of apoptosis in prostate cancer cell lines suggesting that miR-4723-5p is a pro-apoptotic microRNA that regulates prostate carcinogenesis. Analysis of putative miR-4723-5p targets showed that miR-4723-5p targets Integrin alpha 3 (ITGA3) and Methyl CpG binding protein (MeCP2) in addition to Abl1 and Abl2 kinases. In conclusion, we have identified a novel microRNA mediated regulation of Abl tyrosine kinases in prostate cancer. This study suggests that miR-4723-5p may be an attractive target for therapeutic intervention in prostate cancer. Citation Format: Sumit Arora, Sharanjot Saini, Shahana Majid, Varahram Shahryari, Soichiro Yamamura, Takeshi Chiyomaru, Shinichiro Fukuhara, Inik Chang, Guoren Deng, Yuichiro Tanaka, Rajvir Dahiya. MicroRNA 4723-5p is novel tumor suppressor microRNA in prostate cancer that directly regulates Abelson family of nonreceptor protein tyrosine kinases. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3068. doi:10.1158/1538-7445.AM2013-3068
ALLOGENEIC ADIPOSE STEM CELL THERAPY REDUCES APOPTOSIS AND PROMOTES ANTI-INFLAMMATORY MACROPHAGES PHENOTYPE IN A PORCINE MODEL OF ACUTE MYOCARDIAL INFARCTION
Authors: Rodrigo Fernandez-Jimenez, Nuria Solanes, Joaquim Bobi, Carolina Gálvez-Montón, Carlos Galán-Arriola, Jaume Aguero, Leticia Fernandez-Friera, Nadia Castillo, Gonzalo J. López-Martin, Ana García-Alvarez, Mercé Roque, Manel Sabate, Antoni Bayes-Genis, Borja Ibanez, Santiago Roura, Montserrat Rigol
Journal: Journal of the American College of Cardiology (2016)
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
Authors: David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly, B C Cho, Mark A Socinski, Lini Pandite, Christine Nase, Bo Ma, Anthony D'Amelio, Bijoyesh Mookerjee, C Martin Curtis, Bruce E Johnson
Journal: The Lancet Oncology (2016)
Lack of Effect of a Bisphosphonate (Pamidronate Disodium) Infusion on Subsequent Skeletal Uptake of Sm-153 EDTMP
Authors: Carol S Marcus, Sohail Saeed, Anton Mlikotic, Fred Mishkin, H Lee Pham, Theodomyllar Javellana, Saeda Diestelhorst, Craig Minami
Journal: Clinical Nuclear Medicine (2002)

Patients who are candidates for samarium-153 ethylenediaminetetramethylenephosphonic acid (Sm-153 EDTMP) therapy often receive monthly infusions of pamidronate disodium or other bisphosphonates. Because both drugs are related compounds that concentrate in bone, it was advisable to determine whether previous bisphosphonate administration has blocked subsequent uptake of Sm-153 EDTMP. The authors compared skeletal uptake of Sm-153 EDTMP before and 1 to 4 days after pamidronate infusion in three patients with breast cancer metastatic to bone. In two of the patients, they continued to compare Sm-153 EDTMP uptake at approximately 1, 2, 3, and 4 weeks after pamidronate infusion. There was no difference in skeletal uptake of Sm-153 EDTMP before or at any time after pamidronate infusion. Pamidronate infusion did not interfere with skeletal uptake of Sm-153 EDTMP.
Choosing breast reconstruction – for richer, for poorer?.
Authors: T Roe, E Massey, A Chaudhry, R Price, C Chan
Journal: Cancer Research (2009)

Abstract Abstract #5094 OBJECTIVE&amp;#x2028; To assess whether the age or socio-economic status of patients undergoing mastectomy play any part in influencing their decision to undergo breast reconstruction.&amp;#x2028; METHODS&amp;#x2028; Details were collated from all patients undergoing mastectomy with or without reconstruction under the care of a single surgeon at Cheltenham General Hospital over a 5 year period. All patients having a mastectomy were offered a reconstruction. Zip codes were used to assign government deprivation scores and the corresponding national rank for each patient's residential district, according to the 2000 UK national census. Affluent areas have low scores and high rank; deprived areas have high scores and low rank. The Mann-Whitney U test was used to determine whether there was a statistical difference in age or social status between those patients in the mastectomy only group and those who were reconstructed.&amp;#x2028; RESULTS&amp;#x2028; 50 patients underwent mastectomy only (median age 63.5, IQR 52-72), 30 opted for reconstruction (median age 53.5, IQR 44.5-58). There was a statistically significant difference (at the 95% confidence interval) between the average age of the 2 groups (P=0.0002).&amp;#x2028; Median deprivation score for the mastectomy group was 10.4 (6.28-17.84) and for the reconstruction group 9.67 (6.52-17.37). This was not significant (P=0.26).&amp;#x2028; Median ranks were 6224 (4008-7525) and 6511 (2502-7213) respectively (P=0.29).&amp;#x2028; CONCLUSIONS&amp;#x2028; The socio-economic status of patients does not affect their decision on whether or not to undergo post-mastectomy reconstruction. However, younger patients are statistically more likely to opt for a reconstructive procedure. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5094.
THU0368 Familial Mediterranean Fever Associated Spondyloarthritis: A Distinct Pattern of Involvement?
Authors: R. Mercan, A. Turan, B. Bitik, A. Tufan, M.A. Ozturk, B. Goker, S. Haznedaroglu
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Familial Mediterranean fever (FMF) is characterized by recurrent febrile inflammatory attacks of serosal and synovial membranes. Besides well-known febrile attacks, many FMF patients suffer from non-episodic musculoskeletal complaints. Inflammatory back pain is a frequent complaint among FMF patients which is overlooked by physicians. Spondyloarthritis has been observed in 7.5% of FMF patients. However, clinical and radiologic features of this particular patient group are lacking. <h3>Objectives</h3> To determine clinical and radiologic (X-Ray and MRI) characteristics of patients with FMF associated spondyloarthritis (FMF-SPA). <h3>Methods</h3> Twenty-two patients followed up in our clinic with FMF-SPA confirmed by sacroiliac joint MRI were analyzed. All data were retrieved from patient charts. Clinical and radiologic characteristics of these patients were reported. <h3>Results</h3> The mean (min-max) age of patients were 29.2 (19-42) and 54% were female. Mean age at diagnosis of FMF and FMF-SPA were 19.7 (3-40) and 28.5 (19-41), respectively. All patients were negative for HLA-B27. M694V mutation was the most commonly observed MEFV mutation in FMF-SPA patients (77%). Radiographic sacroileitis was evident in 69% of patients. In MRI examination active lesions were observed in 70% of patients. Sacroileitis was bilateral in 77%. There were nine patients with spinal MRI available. Facet joint arthritis was observed in three patients. Vertebral bodies were spared in all. Interestingly, typical chronic spinal lesions of ankylosing spondylitis have not been observed in any of the patients even in those with advanced- stage sacroileitis. <h3>Conclusions</h3> Our results confirmed the role of M694V on risk of spondyloarthritis development in patients with FMF. Furhermore, these results suggest that FMF-SPA might be a distinct type in spondyloarthropathy spectrum diseases. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5260
Is Growth Differentiation Factor 11 a Realistic Therapeutic for Aging-Dependent Muscle Defects?
Authors: Shavonn C. Harper, Andrew Brack, Scott MacDonnell, Michael Franti, Bradley B. Olwin, Beth A. Bailey, Michael A. Rudnicki, Steven R. Houser
Journal: Circulation Research (2016)

This "Controversies in Cardiovascular Research" article evaluates the evidence for and against the hypothesis that the circulating blood level of growth differentiation factor 11 (GDF11) decreases in old age and that restoring normal GDF11 levels in old animals rejuvenates their skeletal muscle and reverses pathological cardiac hypertrophy and cardiac dysfunction. Studies supporting the original GDF11 hypothesis in skeletal and cardiac muscle have not been validated by several independent groups. These new studies have either found no effects of restoring normal GDF11 levels on cardiac structure and function or have shown that increasing GDF11 or its closely related family member growth differentiation factor 8 actually impairs skeletal muscle repair in old animals. One possible explanation for what seems to be mutually exclusive findings is that the original reagent used to measure GDF11 levels also detected many other molecules so that age-dependent changes in GDF11 are still not well known. The more important issue is whether increasing blood [GDF11] repairs old skeletal muscle and reverses age-related cardiac pathologies. There are substantial new and existing data showing that GDF8/11 can exacerbate rather than rejuvenate skeletal muscle injury in old animals. There is also new evidence disputing the idea that there is pathological hypertrophy in old C57bl6 mice and that GDF11 therapy can reverse cardiac pathologies. Finally, high [GDF11] causes reductions in body and heart weight in both young and old animals, suggestive of a cachexia effect. Our conclusion is that elevating blood levels of GDF11 in the aged might cause more harm than good.